Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 7/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553117 | 0.90 | HPGD (0.56) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL3810062 | 0.82 | HPGD (0.62) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL5962241 | 0.82 | ALDH1A1 (0.52) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL7285360 | 0.82 | LMNA (0.77) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL10086154 | 0.81 | LMNA (0.60) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL3001319 | 0.81 | LMNA (0.54) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL13008002 | 0.81 | LMNA (0.58) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL3006569 | 0.80 | LMNA (0.53) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL6814201 | 0.80 | ALDH1A1 (0.50) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL10084828 | 0.79 | LMNA (0.58) | HPGDKDM4EALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590975-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004731-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, INMT, IDO1 | HPGD 810/4885KDM4E 633/4885ALDH1A1 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.